Osimertinib and Capmatinib Combination Therapy to Overcome METY1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report

Osimertinib, a third-generation EGFRtyrosine kinase inhibitor, is the frontline standard in the treatment of metastatic EGFR-mutant NSCLC. Although osimertinib is effective, disease progression occurs in virtually all patients, mediated by a heterogeneous array of resistance mechanisms. Activation of the METsignaling pathway by means of amplification has been implicated in resistance to osimertinib, but activation caused by point mutations in METhas not been well described.